Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy drug
|
| gptkbp:administrativeDivision |
every 3 weeks
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Adriamycin
|
| gptkbp:built |
gptkb:Streptomyces_peucetius
|
| gptkbp:caseTypes |
lung cancer
breast cancer leukemia lymphoma sarcoma |
| gptkbp:chemicalFormula |
C27H29NO11S
|
| gptkbp:contraindication |
allergic reactions
pregnancy heart disease infusion reactions cardiotoxicity lactation secondary malignancies |
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:healthcare |
caution advised
|
| https://www.w3.org/2000/01/rdf-schema#label |
doxorubicin hydrochloride
|
| gptkbp:impact |
antitumor antibiotic
|
| gptkbp:interactsWith |
warfarin
trastuzumab other chemotherapy agents cyclophosphamide |
| gptkbp:is_monitored_by |
cardiac function
kidney function liver function blood counts |
| gptkbp:issuedBy |
injection
|
| gptkbp:locatedIn |
1960s
|
| gptkbp:numberOfStudents |
20-48 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:researchAreas |
clinical trials
pharmacogenomics combination therapies dose optimization resistance studies |
| gptkbp:route |
intravenous
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
nausea hair loss mouth sores low blood cell counts |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
intercalates DNA
inhibits topoisomerase II |
| gptkbp:usedFor |
treating cancer
|
| gptkbp:waterManagement |
urine
bile |
| gptkbp:weight |
579.65 g/mol
|